First AD

Second AD

Additional Second-Line Treatments for HCC

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


Insights

Insights is an expert interview video series of leading oncologists that provides in-depth reports and feature segments profiling leaders in a range of oncology disciplines, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, and hematologic malignancies. Most episodes feature 2 clinicians discussing the latest oncology advances in clinical practice. 

Video Series

The Role of Tyrosine Kinase Inhibitors in Unresectable Hepatocellular Carcinoma

Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, discuss a novel therapy that, although not practice-changing, provides an additional treatment option for patients with hepatocellular carcinoma. 

Examining the Role of Liver Function in HCC

HCC Staging: Improving Treatment Strategies

Locoregional Therapies for Intermediate-Stage HCC

HCC Trials: Insights from the LAUNCH, EMERALD-1, and LEAP-012 Trials

Emerging Therapies in Intermediate-Stage HCC 

Updates from IMbrave150, LEAP-002, and HIMALAYA Trials 

Comorbidity Considerations for HCC Treatment

The Evolving Landscape of Second-Line Therapies in HCC Management

Real-World Evidence on Second-Line Therapy Selection and Outcomes 

Pioneering Breakthroughs in HCC Treatment